Apom-fc fusion proteins for treating lung diseases
US-2021380665-A1 · Dec 9, 2021 · US
ApoM-Fc fusion proteins and uses thereof
US12559540B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12559540-B2 |
| Application number | US-201816639445-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 15, 2018 |
| Priority date | Aug 15, 2017 |
| Publication date | Feb 24, 2026 |
| Grant date | Feb 24, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are engineered fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG). In some embodiments, the ApoM-Fc fusion protein further comprises a signal peptide (e.g., IL-2 signal peptide) fused to the ApoM, allowing the fusion protein to be secreted once expressed recombinantly. Methods of using the ApoM-Fc fusion protein or the sponge variants in the treatment of various diseases or disorders are provided.
First claim
Opening claim text (preview).
What is claimed is: 1 . A fusion protein comprising an apolipoprotein M (ApoM) fused to a constant region (Fc) of an immunoglobulin (IgG), wherein the fusion protein comprises an amino acid sequence that is at least 99.5% identical to SEQ ID NO: 1. 2 . The fusion protein of claim 1 , wherein the ApoM comprises one or two amino acid substitutions at positions selected from the group consisting of positions T42, V46, I68, and M70 in SEQ ID NO: 5. 3 . The fusion protein of claim 1 , wherein the ApoM comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 5. 4 . The fusion protein of claim 2 , wherein the ApoM comprises the amino acid sequence of any one of SEQ ID NOs: 9-15. 5 . The fusion protein of claim 1 , wherein the fusion protein comprises the amino acid sequence of any one of SEQ ID NOs: 23-29. 6 . The fusion protein of claim 1 , comprising the amino acid sequence of SEQ ID NO: 1. 7 . A nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein of claim 1 . 8 . A method of producing a fusion protein, comprising culturing a cell comprising the nucleic acid molecule of claim 7 in a culturing media, under conditions that allow the fusion protein to express.
Assignees
Inventors
Classifications
DNA sequences coding for fusion proteins · CPC title
Double-stranded nucleic acids or oligonucleotides · CPC title
Cells modified by introduction of foreign genetic material · CPC title
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title
containing a signal sequence · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12559540B2 cover?
- Provided herein are engineered fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG). In some embodiments, the ApoM-Fc fusion protein further comprises a signal peptide (e.g., IL-2 signal peptide) fused to the ApoM, allowing the fusion protein to be secreted once expressed recombinantly. Methods of…
- Who is the assignee on this patent?
- Childrens Medical Center
- What technology area does this patent fall under?
- Primary CPC classification C07K14/775. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).